Meta‐analysis: analysis of mechanistic pathways in the treatment of non‐alcoholic steatohepatitis. Evidence from a Bayesian network meta‐analysis. Issue 9 (14th March 2022)

• Record Type: Journal Article
• Authors: Ng, Cheng Han; Muthiah, Mark D.; Xiao, Jieling; Chin, Yip Han; Lim, Grace; Lim, Wen Hui; Tay, Phoebe; Tan, Darren Jun Hao; Yong, Jie Ning; Pan, Xin‐Hui; Koh, Jeffery Wei Heng; Chew, Nicholas; Syn, Nicholas; Tan, Eunice; Huang, Daniel Q.; Siddiqui, Mohammad Shadab; Loomba, Rohit; Sanyal, Arun J.; Noureddin, Mazen
• Is Part Of: Alimentary pharmacology & therapeutics. Volume 55:Issue 9(2022)
• Page Start: 1076
• Page End: 1087
• Publication Date: 2022-03-14
• Subjects: drug therapy -- fibrosis -- non‐alcoholic fatty liver disease -- steatosis -- treatment outcome; Digestive organs -- Diseases -- Treatment -- Periodicals; Digestive organs -- Effect of drugs on -- Periodicals; Gastrointestinal system -- Diseases -- Treatment -- Periodicals; Gastrointestinal system -- Effect of drugs on -- Periodicals; 615.73
• DOI: 10.1111/apt.16808
• Languages: English
• ISSNs: 0269-2813

Abstract

Summary: Background and Aims: Non‐alcoholic steatohepatitis (NASH) is the most common cause of liver disease. However, there is lack of comparison of efficacy between different NASH drug classes. We conducted a network meta‐analysis evaluating drug classes through comparing histological outcomes and targets of drugs. Approach and Results: Medline, EMBASE and CENTRAL were searched for randomised controlled trials evaluating NASH drugs in biopsy‐proven NASH patients. Primary outcomes included NASH resolution without worsening of fibrosis, at least 2‐point reduction in Non‐alcoholic fatty liver disease Activity Score (NAS) without worsening of fibrosis and at least 1‐point reduction in fibrosis. Treatments were classified into inflammation, energy, bile acid and fibrosis modulators. The analysis was conducted with Bayesian network model and surface under the cumulative ranking curve (SUCRA) analysis. Among 49 included trials, treatments modulating energy (Risk ratio (RR): 1.92, Credible intervals (Crl): 1.59‐2.34) were most likely to achieve NASH resolution followed by treatments modulating fibrosis (RR 1.66, Crl: 0.65‐4.50), bile acids (RR: 1.37, Crl: 0.99‐1.92) and inflammation (RR: 1.00, Crl: 0.75‐1.33). Energy and bile acids modulation were effective in at least 2‐point NAS reduction without worsening of fibrosis (RR: 1.52, Crl 1.30‐1.77; RR: 1.69, Crl 1.41‐2.03) and at least 1‐point reduction in fibrosis (RR: 1.26, Crl:1.05‐1.49; RR: 1.54, Crl: 1.20‐1.97). Conclusions: This network analysis demonstrates the relative superiority of drugs modulating energy pathways and bile acids in NASH treatment. This guides the development and selection of drugs for combination therapies. Abstract : A Bayesian network meta‐analysis of mechanistic pathway in the treatment of Non‐Alcoholic Steatohepatitis (NASH)